Elena Lewis, MD
Allergy · Portage, MINPI 1194928994
Payments from drug & device makers
Across 574 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Novartis$992
- Takeda Pharmaceuticals U.S.A., Inc.$858
- Grifols USA, LLC$693
- Sanofi$693
- plus $5K from 30 others
What the payments were for
- Food & beverage$10,93598%
- Education$2292%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 89 | $1,771 |
| GSK | 103 | $1,191 |
| Novartis | 57 | $992 |
| Takeda Pharmaceuticals U.S.A., Inc. | 37 | $858 |
| Grifols USA, LLC | 27 | $693 |
| Sanofi | 27 | $693 |
| Regeneron Healthcare Solutions, Inc. | 18 | $579 |
| Biocryst US Sales Co., LLC | 22 | $532 |
| Genentech USA, Inc. | 22 | $465 |
| Pfizer | 24 | $462 |
| Optinose US, Inc. | 19 | $352 |
| Alk-abello, Inc | 16 | $342 |
| CSL Behring | 16 | $327 |
| Boehringer Ingelheim | 16 | $248 |
| Aimmune Therapeutics, Inc. | 10 | $214 |
| Amgen | 10 | $199 |
| Kaleo, Inc. | 9 | $167 |
| Blueprint Medicines Corporation | 6 | $162 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $126 |
| Lilly USA, LLC | 6 | $119 |
| LEO Pharma Inc. | 5 | $109 |
| Teva Pharmaceuticals USA, Inc. | 6 | $96 |
| Covis Pharma GmbH | 5 | $65 |
| Pharming Healthcare, Inc. | 2 | $63 |
| Verona Pharma, Inc. | 3 | $60 |
| Incyte Corporation | 2 | $45 |
| Shire North American Group Inc | 2 | $41 |
| Hospira, Inc. | 2 | $38 |
| Biocryst Pharmaceuticals, Inc. | 2 | $37 |
| Organon | 1 | $25 |
| AbbVie | 1 | $20 |
| Viatris Specialty LLC | 1 | $17 |
| Merck | 1 | $17 |
| Phadia US Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
How this compares
$11,164 in reported general payments places this provider in the 80th percentile of 22 allergy providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 95 | $375,304 |
| XolairOmalizumab | 37 | $105,999 |
| TezspireTezepelumab-Ekko | 15 | $97,241 |
| Fasenra PenBenralizumab | 16 | $96,857 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 109 | $89,300 |
| AdbryTralokinumab-Ldrm | 12 | $47,693 |
| Spiriva RespimatTiotropium Bromide | 36 | $30,335 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $29,054 |
| Advair HfaFluticasone Propion/Salmeterol | 54 | $21,536 |
| DuleraMometasone/Formoterol | 44 | $19,373 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $18,624 |
| Serevent DiskusSalmeterol Xinafoate | 17 | $10,587 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $8,632 |
| Wixela InhubFluticasone Propion/Salmeterol | 28 | $8,145 |
| Cromolyn Sodium | 37 | $7,918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Pulmicort Flexhaler | $1,771 | $128,12273 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,191 | $123,555174 claims |
| LEO Pharma Inc.Adbry | $109 | $47,69312 claims |
| Boehringer IngelheimSpiriva Respimat | $248 | $30,33536 claims |
| MerckDulera | $17 | $19,37344 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $96 | $5,67318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 22 allergy providers in Michigan.
Other allergy in Portage
- Chad MayerFarmington Hills$25K
- Ravinder PolasaniJackson$18K
- Mutee AbdeljaberCaro$12K
- James McClellanTraverse City$11K
- Byra ReddySaint Joseph$9K
- Seshagiri DandamudiBattle Creek$7K
- Jasmine AlsukhonNovi$6K
- Claire WardTraverse City$3K
- Lokesh EdaraBattle Creek$3K
- Anna DobrackiBrighton$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.